Ireland
--:--IST
Latest
Clinical Trials in Switzerland / NCT06624709
Recruiting Not applicable

The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution

NCT06624709 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Riccardo Pfister
Phase
Not applicable
Started
2024-11-02
Last updated
2025-05-25

Condition(s) studied

Premature Birth

Investigational drug(s) / intervention(s)

Iron Supplement

Iron Supplement: The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week

Study summary

BienFer is a double-blinded randomized controlled trial about iron substitution and abdominal pain. Premature babies and low birth weight babies have lower iron stores than term newborns and are therefore at greater risk of iron deficiency and anemia. Iron deficiency could have consequences for cerebral development. Ferric substitution reduces the risk of iron deficiency and anemia. It is common to replace premature babies with iron substitution between 2 weeks and 6 months of life. In practice, the medical staff notice that newborn with iron substitution have abdominal pain and constipation. A study in the adult population shows that alternate iron supplementation versus daily supplementation improved iron absorption, with no difference in hemoglobin level and decrease abdominal pain. Studies in children shows that intermittent iron supplementation do not change hemoglobin and ferritin level and improve adherence. There is no data comparing daily versus alternate supplementation in premature babies.

The aim of the study is to evaluate if alternate (4 times/week) iron supplementation is equivalent to daily iron substitution for hemoglobin values in premature babies between 28 0/7 weeks amenorrhea (WA) and 34 6/7 WA, and if it reduces abdominal discomfort and inflammation, and if it improves compliance.

Eligibility

Sex
ALL
Min age
14 Days
Max age
14 Days
Healthy volunteers
Accepted
Inclusion Criteria: * Premature babies between 28 0/7WA and 34 6/7 WA * Parental consent, postnatal * Age of 2 weeks Exclusion Criteria: * anemia \< 80g/l at 2 weeks of age * Intraventricular Hemorrhage stage III and IV * Necrotizing Enterocolitis * Enteral feeding less than 100ml/kg/j after 2 weeks of life * Congenital disorder

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
HUG Geneva Canton of Geneva Recruiting
CHUV Lausanne Canton of Vaud Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06624709 on ClinicalTrials.gov ↗ ← All trials in Switzerland